Skip to content

ACS Chemical Neuroscience

ISSN 1948-7193

100 papers in the library · 2,538 citations · publishing 2010-2026

Papers

Sort Most recent Most cited

Next-Generation Psychedelic Drug Development

ACS Chemical Neuroscience September 15, 2026 Lindsay P. Cameron, Matthew W. Johnson, Kevin S. Murnane et al.

Psychedelic medicine has gained rapid popularity for the treatment of a variety of neuropsychiatric disorders, including depression, anxiety, and post-traumatic stress disorder. As novel psychedelic analogues and treatment regimes emerge, increasing numbers of variables are being tested. Here, we review various approaches and considerations for novel psychedelic therapies, including the...

Proliferative Effects of the Psychedelic N,N-Dimethyltryptamine (DMT) in Human Neural Stem Cells.

ACS Chemical Neuroscience July 9, 2026 José Alexandre Salerno, Elizabeth R. Dominguez, Karina Karmirian et al.

The serotonergic psychedelic N,N-dimethyltryptamine (DMT) produces rapid antidepressant effects in preclinical and early clinical studies. Therapeutic benefits have been linked to sustained neural plasticity, including adult neurogenesis in rodents. Whether brief DMT exposure engages proliferative responses in human neural stem cells (NSCs) remains unresolved. Using human iPSC-derived NSCs, we...

DOI: 10.1021/acschemneuro.6c00209 (opens in new tab) Full text (opens in new tab) Bdnf N,N-Dimethyltryptamine DMT Cell cycle Neurosphere

Short- and Long-Acting Psychedelics: Structure-Activity Relationships, Pharmacology, and Implications for Neuropsychiatric Therapeutics.

ACS Chemical Neuroscience June 17, 2026 Anoushka Bhat, Elmira Zolali, Mahfuz A Sakib et al.

Psychedelics have re-emerged as promising therapeutics for neuropsychiatric disorders, including depression, anxiety, post-traumatic stress disorder, and substance use disorders. While their beneficial effects are largely attributed to serotonin 2A (5-HT2A) receptor activation, psychedelics exhibit substantial diversity in chemical structure, receptor binding kinetics, metabolism, and duration...

Serotonin Transporter Blockade Reduces the Psychedelic-Like Effects of 4-Methoxy- N -methyl- N -isopropyltryptamine and Related Analogs

ACS Chemical Neuroscience May 27, 2026 Grant C. Glatfelter, Serena S. Schalk, Donna Walther et al.

High Resolution Image Download MS PowerPoint Slide Tryptamine psychedelics induce psychoactive effects via agonist actions at serotonin 2A receptors (5-HT 2A ), but the compounds are generally nonselective. 4-Methoxy- N -methyl- N -isopropyltryptamine (4-MeO-MiPT) is a 5-HT 2A agonist which also blocks the 5-HT transporter (SERT) and has blunted visual and other psychedelic effects in humans....

DOI: 10.1021/acschemneuro.6c00083 (opens in new tab) Serotonin transporter Tryptamine Partial agonist Blockade +8

Synthesis of Clausenamide Isomers and Evaluation of Their Potential as Cortical Neuroplastogens.

ACS Chemical Neuroscience May 20, 2026 Yongyu Ou, Yara A Khatib, Adam Mosswood et al.

Neuroplastogens, small molecules that induce beneficial neuronal growth and plasticity, are a class of compounds emerging as new drugs for treating a range of central nervous system conditions. Clausenamide is a plasticity-promoting natural product isolated from the leaves of Clausena lansium, an evergreen native to Southeast Asia and southern China. Herein, we report an efficient synthesis of...

DOI: 10.1021/acschemneuro.5c00767 (opens in new tab) Full text (opens in new tab) 5-ht2a partial agonist Clausenamide Multi-component reaction Neuroplastogen +2

R-MDDMA is a Safer Analogue of MDMA with Therapeutic Potential.

ACS Chemical Neuroscience May 6, 2026 Maxemiliano V. Vargas, Cassandra J. Hatzipantelis, Lee E. Dunlap et al.

Recent clinical evidence suggests that racemic 3,4-methylenedioxymethamphetamine (MDMA) might be useful for treating a range of neuropsychiatric diseases including post-traumatic stress disorder (PTSD) and depression. However, concerns about its abuse potential stemming from its monoamine releasing properties have hampered its clinical development. Thus, safer analogues of racemic MDMA with...

N-Benzyl-tryptamine Derivatives as Serotonin 5-HT2A Receptor (5-HT2AR) Agonists: Focus on Different In Vitro 5-HT2AR Activity Profiles.

ACS Chemical Neuroscience March 20, 2026 Eline Pottie, Emma Vertriest, Darío Martínez-afani et al.

N-Benzyl-derived phenethylamines are highly active (psychedelic) 5-HT2AR (serotonin 2A receptor) agonists used as biochemical tools and on the drug market. The impact of adding an N-benzyl substituent to the tryptamine core structure has scarcely been studied. A recent systematic exploration of N-benzyl-substituted (5-MeO-)tryptamines revealed a surprisingly low activity in a Ca2+ mobilization...

Correction to "Next-Generation MDMA Analogue SDMA: Pharmacological and Metabolic Insights".

ACS Chemical Neuroscience March 4, 2026 Nina Kastner, Núria Nadal‐gratacós, Selina Hemmer et al. correction

Correction 1: Table 1.The analyses were conducted using the correct data, and all results, interpretations, and conclusions in the paper remain fully accurate.The issue is limited to the presentation of values in the table.Correction 2: p 4733, second paragraph, 1 st sentence.Thigmotaxis was evaluated to assess potential anxiety-like effects induced by the compounds.When comparing the tested...

Synthesis and Characterization of Psilocybin Metabolites and Deuterated Analogs

ACS Chemical Neuroscience March 3, 2026 Samuel E. Williamson, Elise K. Burkhartzmeyer, Michael T. Faley et al.

To support ongoing clinical trials, the major human metabolites of psilocybin were synthesized on a preparative scale, specifically psilocin-O-glucuronide and 4-hydroxyindole-3-acetic acid (4-HIAA), along with putative minor metabolites and several deuterium-labeled derivatives. Psilocybin, psilocin, psilocin-O-glucuronide, and 4-HIAA were assayed for engagement at seven serotonin receptor...

Rewiring Receptor Activation: Mechanistic Insights into Toggle Switch Modulation by 25CN-NBx Compounds

ACS Chemical Neuroscience February 18, 2026 Vito F. Palmisano, Micaela Vidal−sánchez, Juan J. Nogueira

High Resolution Image Download MS PowerPoint Slide The development of new treatments for neuropsychiatric disorders relies on a deeper understanding of the molecular mechanisms behind psychedelic compounds, particularly how they differentiate between hallucinogenic and antidepressant effects. In this study, we explore by molecular dynamics simulations a series of 25CN-NBx compounds bound to the...

DOI: 10.1021/acschemneuro.6c00023 (opens in new tab) Dihedral angle Molecular dynamics Receptor Molecular mechanics +4

Adult Rat Offspring Exposed to THC during Gestation Exhibit Distinct Biomolecular Changes Identified by X-ray Fluorescence Imaging and Fourier Transform Infrared Spectroscopy in Cortico-Limbic Circuits.

ACS Chemical Neuroscience February 18, 2026 Tallan Black, Rhiannon E Boseley, Amanda Quirk et al.

Perspectives surrounding Cannabis use have transformed over the past decade. This shift in perspective has been noted in pregnant populations in Canada and the US, where various investigations report that the use of Cannabis in pregnancy is increasingly commonplace. There is some evidence indicating that Δ9-tetrahydrocannabinol (THC), the main intoxicating phytocannabinoid found within Cannabis...

Zalsupindole: A Non-Hallucinogenic Psychoplastogen Advancing Psychedelic-Inspired Therapeutics.

ACS Chemical Neuroscience January 21, 2026 Miguel Salfiti, Marios Kyriazis, Georgios Mikellides 2 citations

This review aims to evaluate the pharmacological properties, mechanistic selectivity, and early clinical development of zalsupindole, highlighting its potential as a next-generation psychiatric therapeutic. This review was conducted using a structured literature search strategy across PubMed, Google Scholar, ClinicalTrials.gov, and the official Web sites of regulatory bodies and pharmaceutical...

Psychedelic Modulation of Excitation/Inhibition Balance: A Dual-Phase Neurodevelopmental Model.

ACS Chemical Neuroscience January 7, 2026 Charalampos L. Kandilakis, Costas Papatheodoropoulos

Psychedelics are a diverse class of psychoactive compounds that profoundly alter perception, cognition, and emotional states. Recently, classical serotonergic agents, such as psilocybin and lysergic acid diethylamide (LSD), along with atypical agents such as methylenedioxymethamphetamine (MDMA, ecstasy) and ibogaine, have attracted renewed attention due to their rapid and sustained clinical...

Snapshot IP 1 Detection Following 5-HT 2 A Receptor Stimulation in the Mouse Brain

ACS Chemical Neuroscience January 2, 2026 Mario de la Fuente Revenga, Javier González-Maeso 1 citation

The distinct subjective effects that define psychedelics such as lysergic acid diethylamide (LSD), psilocybin, or 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) as drug class are causally linked to the activation of the serotonin 2A receptor (5-HT 2A R). However, some aspects of 5-HT 2A R pharmacology remain elusive, such as what molecular drivers differentiate psychedelic from...

Dual Modulation of 5-HT2A Receptors and SERT by α-Ethyltryptamine and Its Optical Isomers.

ACS Chemical Neuroscience December 17, 2025 Justin M Silverman, Michael Fiorillo, Jason Younkin et al. 1 citation

α-Ethyltryptamine (AET), a synthetic tryptamine formerly used as an antidepressant, has resurfaced as a compound of interest due to its structural and functional overlap with serotonergic psychedelics and entactogens. Here, we characterized the pharmacological properties of racemic AET and its optical isomers, R(-)-AET and S(+)-AET, focusing on their interactions with the serotonin (or...

DOI: 10.1021/acschemneuro.5c00468 (opens in new tab) Full text (opens in new tab) 5-ht2a receptor G protein-coupled receptor Head-twitch response Psychedelics +3

Next-Generation MDMA Analogue SDMA: Pharmacological and Metabolic Insights

ACS Chemical Neuroscience December 2, 2025 Nina Kastner, Núria Nadal‐gratacós, Selina Hemmer et al.

3,4-Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, shows promise in treating depression and post-traumatic stress disorder (PTSD), resulting in breakthrough status. However, concerns regarding MDMA's abuse potential and cytotoxicity have sparked interest in developing safer analogues with similar therapeutic benefits. This study investigated the pharmacological properties of...

DOI: 10.1021/acschemneuro.5c00782 (opens in new tab) MDMA Norepinephrine transporter Monoamine neurotransmitter Dopamine transporter +8

Simple Analogs of the LSD D-Ring: A Consideration of Structure-Activity Relationships and Their Potential as Therapeutics.

ACS Chemical Neuroscience November 5, 2025 Steven A. Barker 1 citation

Psychedelic drugs have begun to show therapeutic promise. However, there is a growing research effort focused on creating nonhallucinogenic analogs of these substances. The goal is to develop new treatments for an expanding list of psychiatric and neurodegenerative disorders, while eliminating the complications and costs of treatment engendered by the subjective psychedelic experience....

Indolethylamine N-Methyltransferase Deletion Impacts Mouse Behavior without Disrupting Endogenous Psychedelic Tryptamine Production.

ACS Chemical Neuroscience October 15, 2025 Cassandra J. Hatzipantelis, Lindsay P. Cameron, Min Liu et al.

Exogenously administered psychedelics produce both rapid and long-lasting effects on neuroplasticity and behavior, but it is currently unclear if endogenously produced psychedelics can elicit similar effects. There have been relatively few studies on the role of endogenous psychedelics in health and disease, perhaps owing to the difficulty in quantifying their levels and manipulating their...

Zalsupindole is a Nondissociative, Nonhallucinogenic Neuroplastogen with Therapeutic Effects Comparable to Ketamine and Psychedelics

ACS Chemical Neuroscience October 13, 2025 Rajiv Agrawal, Daniel J. Gillie, Alison E. Mungenast et al. 8 citations

Many neuropsychiatric conditions, including depression, involve synaptic loss and atrophy of the prefrontal cortex. The rapid regrowth of cortical neurons has been hypothesized to explain the rapid and enduring therapeutic effects of psychedelics and the dissociative anesthetic ketamine. However, safety concerns related to hallucinogenic/dissociative properties have limited the addressable...

Serotonin 5-HT2C Receptor Signaling Analysis Reveals Psychedelic Biased Agonism.

ACS Chemical Neuroscience September 13, 2025 Emma M. Bonniwell, Rana Alabdali, Joseph J. Hennessey et al. 3 citations

The serotonin 2C receptor (5-HT 2C ) is a G protein-coupled receptor implicated in multiple physiological and psychological processes and has been investigated as a therapeutic target for neuropsychiatric conditions such as obesity, drug abuse, and depression. With renewed interest in serotonergic psychedelics for treating depression, 5-HT 2C may contribute to psychedelic-induced therapeutic...

DOI: 10.1021/acschemneuro.5c00647 (opens in new tab) Full text (opens in new tab) Psychedelics Hallucinogens Entheogens Mind-altering drugs +18

Pharmacological Evaluation of Tropane Analogues at the Serotonin Transporter.

ACS Chemical Neuroscience September 3, 2025 Arabo A. Avanes, Hunter T Warren, Abinaya Senthil et al. 2 citations

Tropane alkaloids and their derivatives represent a diverse class of small molecules with a broad range of therapeutic applications. Many tropanes regulate synaptic levels of neuromodulators by interacting with monoamine transporters such as dopamine (DAT) and serotonin (SERT) transporters. While DAT inhibition plays an important role in the addictive potential of tropanes such as cocaine,...

Exploring Esketamine's Therapeutic Role for Perinatal Depression via TASK-1 Tandem Pore Potassium Channels.

ACS Chemical Neuroscience July 29, 2025 Lin Zhu, Ji Chen, Yuan Liu et al. 1 citation

This research focuses on the promising use of esketamine in perinatal depression, a widespread disorder impacting postpartum women's mental health. Despite esketamine's known rapid antidepressant effects, its precise mechanisms are not fully understood. This study integrates clinical and preclinical approaches to explore esketamine's efficacy in treating perinatal depression and its actions...

Psychedelics, Spirituality, and Fundamentalism: A Brain Network Approach to Cognitive Flexibility and Rigidity

ACS Chemical Neuroscience July 24, 2025 Anjian Yang, Xinyou Lv, Hongshuang Wang et al. 1 citation

This viewpoint reconceptualizes mysticism and fundamentalism as brain network disorders, with psychedelics like psilocybin, lysergic acid diethylamide, and N,N-dimethyltryptamine offering potential to modulate these states. By disrupting rigid neural patterns, psychedelics may foster cognitive flexibility, challenge inflexible belief systems, and offer therapeutic value for extremism and mental...

DOI: 10.1021/acschemneuro.5c00509 (opens in new tab) Extremism Fundamentalism Terrorism Rigid thinking +10

Psychedelics and the Gut Microbiome: Unraveling the Interplay and Therapeutic Implications.

ACS Chemical Neuroscience July 9, 2025 Xue Wang, Fan Jun, Cong Lin et al. 4 citations

Classic psychedelics and the gut microbiome interact bidirectionally through mechanisms involving 5-HT2A receptor signaling, neuroplasticity, and microbial metabolism. This viewpoint highlights how psychedelics may reshape microbiota and how microbes influence psychedelic efficacy, proposing microbiome-informed strategies─such as probiotics or dietary interventions─to personalize and enhance...